Zacks: Analysts Anticipate Ionis Pharmaceuticals Inc (IONS) Will Post Earnings of -$0.11 Per Share
Equities analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to announce ($0.11) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is $0.10 and the lowest is ($0.39). The company is scheduled to report its next earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.36) per share for the current year, with EPS estimates ranging from ($1.10) to $0.03. For the next year, analysts forecast that the business will post earnings of $0.25 per share, with EPS estimates ranging from ($1.60) to $2.49. Zacks’ EPS averages are an average based on a survey of analysts that follow Ionis Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, August 7th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.20). The company had revenue of $117.75 million for the quarter, compared to analyst estimates of $128.22 million. Ionis Pharmaceuticals had a negative return on equity of 1.22% and a negative net margin of 7.20%.
In related news, Director Frederick T. Muto sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 31st. The shares were sold at an average price of $46.45, for a total transaction of $696,750.00. Following the completion of the sale, the director now owns 22,127 shares of the company’s stock, valued at $1,027,799.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP C Frank Bennett sold 12,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 8th. The shares were sold at an average price of $45.00, for a total transaction of $562,500.00. Following the sale, the senior vice president now directly owns 19,409 shares of the company’s stock, valued at approximately $873,405. The disclosure for this sale can be found here. Insiders have sold 42,656 shares of company stock valued at $1,901,087 over the last quarter. Company insiders own 2.44% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Baillie Gifford & Co. lifted its stake in shares of Ionis Pharmaceuticals by 48.2% during the 2nd quarter. Baillie Gifford & Co. now owns 9,279,730 shares of the company’s stock valued at $386,687,000 after buying an additional 3,017,079 shares in the last quarter. Summit Trail Advisors LLC lifted its stake in Ionis Pharmaceuticals by 2,960.4% in the 1st quarter. Summit Trail Advisors LLC now owns 523,108 shares of the company’s stock worth $523,000 after purchasing an additional 506,015 shares in the last quarter. First Light Asset Management LLC lifted its stake in Ionis Pharmaceuticals by 1,064.2% in the 2nd quarter. First Light Asset Management LLC now owns 494,347 shares of the company’s stock worth $20,599,000 after purchasing an additional 451,883 shares in the last quarter. BB Biotech AG increased its holdings in shares of Ionis Pharmaceuticals by 4.7% in the 1st quarter. BB Biotech AG now owns 8,516,334 shares of the company’s stock worth $375,400,000 after buying an additional 380,000 shares during the last quarter. Finally, Peregrine Capital Management LLC bought a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter worth about $13,616,000. 94.19% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:IONS opened at $51.42 on Tuesday. The stock has a market capitalization of $6.69 billion, a PE ratio of 642.75 and a beta of 2.66. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.34 and a current ratio of 8.38. Ionis Pharmaceuticals has a 1 year low of $39.07 and a 1 year high of $65.51.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Featured Story: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.